Certain drugs that are initiated by a specialist but are suitable for GPs to continue ongoing prescribing. The specialist should provide the GP with necessary information and support in order for treatment to be managed safely in primary care. Shared care protocols (SCP) or prescribing guidelines may be available.
1. Requiring specialist assessment to enable patient selection.
2. Requiring a period of monitoring by a specialist.
3. The initial prescription should normally be issued by the specialist unless the agreed SCP states otherwise.
A drug which should not be initiated in Sheffield unless exceptional circumstances apply to the individual concerned and an Individual Funding Request (IFR) has been agreed by NHS Sheffield.
The drug should not be withdrawn from patients already established on treatment but other treatment options should be considered at routine review.
1. There is a clear Yorkshire and Humber Specialised Commissioning Group decision to not routinely fund usage of the drug.
2. There is a NICE recommendation that the drug should not be prescribed on the NHS for the condition specified.
3. A drug requiring specific commissioning arrangements to be clarified and put in place before prescribing can take place.
Drugs for which GPs should take full responsibility for initiating and ongoing prescribing.
Prescribing and ongoing supply is normally undertaken by a consultant or other physician within a secondary care service. In some exceptional circumstances and following discussion between primary and secondary care, GPs may consider it to be in the patient’s best interest for drugs in the Red section of the traffic light scheme to be prescribed in primary care.
Red traffic light drugs meet one or more of the following criteria:
1. Require specialist assessment to enable patient selection, initiation, ongoing treatment and monitoring of efficacy, toxicity or adverse effects.
2. Specifically designated as “hospital only “either by product licence or by DH
3. Hospital initiated clinical trial materials used in accordance with the trial protocol
4. Not listed in the current BNF or BNF (C).
5. Being used to treat a condition that is not suitable for primary care prescribing because of disease specific requirements, complexity or defined commissioning arrangements.